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Background-—Biomarkers of myocardial injury increase frequently during transcatheter aortic valve implantation (TAVI). The
impact of postprocedural cardiac troponin (cTn) elevation on short-term outcomes remains controversial, and the association with
long-term prognosis is unknown.
Methods and Results-—We evaluated 577 consecutive patients with severe aortic stenosis treated with TAVI between 2007 and
2012. Myocardial injury, deﬁned according to the Valve Academic Research Consortium (VARC)-2 as post-TAVI cardiac troponin T
(cTnT) >159 the upper limit of normal, occurred in 338 patients (58.1%). In multivariate analyses, myocardial injury was associated
with higher risk of all-cause mortality at 30 days (adjusted hazard ratio [HR], 8.77; 95% CI, 2.07–37.12; P=0.003) and remained a
signiﬁcant predictor at 2 years (adjusted HR, 1.98; 95% CI, 1.36–2.88; P<0.001). Higher cTnT cutoffs did not add incremental
predictive value compared with the VARC-2–deﬁned cutoff. Whereas myocardial injury occurred more frequently in patients with
versus without coronary artery disease (CAD), the relative impact of cTnT elevation on 2-year mortality did not differ between
patients without CAD (adjusted HR, 2.59; 95% CI, 1.27–5.26; P=0.009) and those with CAD (adjusted HR, 1.71; 95% CI, 1.10–2.65;
P=0.018; P for interaction=0.24). Mortality rates at 2 years were lowest in patients without CAD and no myocardial injury (11.6%)
and highest in patients with complex CAD (SYNTAX score >22) and myocardial injury (41.1%).
Conclusions-—VARC-2–deﬁned cTnT elevation emerged as a strong, independent predictor of 30-day mortality and remained a
modest, but signiﬁcant, predictor throughout 2 years post-TAVI. The prognostic value of cTnT elevation was modiﬁed by the
presence and complexity of underlying CAD with highest mortality risk observed in patients combining SYNTAX score >22 and
evidence of myocardial injury. ( J Am Heart Assoc. 2016;5:e002430 doi: 10.1161/JAHA.115.002430)
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T ranscatheter aortic valve implantation (TAVI) has evolvedinto a valuable treatment modality in high-risk and
inoperable patients with severe aortic stenosis (AS)1–3;
however, individual risk stratiﬁcation and long-term prognos-
tication remain challenging. While biomarkers of myocardial
necrosis increase and predict adverse outcomes after coro-
nary interventions,4 growing interest has focused on the
clinical signiﬁcance of myocardial injury that frequently occurs
during TAVI. Previous studies have yielded conﬂicting results,
with some investigations showing an impact of cardiac
troponin (cTn) elevation on post-TAVI outcomes5–7 and others
dissociating postprocedural cTn levels from subsequent
adverse events.8,9 Previous reports were limited by smaller
patient numbers and shorter duration of follow-up and did not
assess prognostic implications of cTn elevation according to
the presence and complexity of coronary artery disease
(CAD), despite the fact that coexisting coronary atheroscle-
rosis varies substantially among patients with AS10 and
affects the magnitude of myocardial necrosis during TAVI
interventions.8 Most notably, earlier investigations applied
distinctly different cutoffs of cTn to deﬁne myocardial injury,
ranging from any increase,7,9 59 increase,6 and up to 159
the upper limit of normal (ULN),5,8 such that the proportion of
patients with reported cTn elevation ranged from 17% to 99%.
Using the current Valve Academic Research Consortium
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(VARC)-2 cTn cutoff of 159 ULN to deﬁne myocardial injury,11
2 studies have reported discordant results regarding the
predictive merit of cTnT elevation post-TAVI.5,8
Currently, the association of TAVI-related cTn increase
with short-term outcomes remains controversial; the effect of
the VARC-2–deﬁned threshold of myocardial injury on long-
term survival and the interrelation with the presence and
severity of underlying CAD are unknown, and the relative
predictive value of pre- versus post-TAVI cTn measurement
has only undergone limited investigation. Against this
background, this study sought to determine the impact of
VARC-2–deﬁned myocardial injury on clinical outcomes in a
sizeable cohort of consecutive patients with severe AS
undergoing TAVI.
Methods
Patient Population
This is a retrospective analysis of prospectively collected data.
All patients with severe native-valve AS (deﬁned as indexed
aortic valve area [AVA] ≤0.6 cm2/m2 or mean gradient
>40 mm Hg) who underwent TAVI at our institution between
August 2007 and December 2012 were entered into a
dedicated database (Bern TAVI Registry). Patients were
deemed inoperable or at high surgical risk by a multidisci-
plinary Heart Team. Of 606 consecutive patients, 577 (95.2%)
had measurements of cTnT after the intervention and are
included in the present analysis. The study was approved by
the local Ethics Committee, and all patients provided written
informed consent for prospective follow-up.
Hemodynamic and Echocardiographic
Assessment
Patients underwent coronary angiography as well as left and
right heart catheterization for hemodynamic assessment
before TAVI. Aortic valve gradients were measured by the
pull-back technique from the left ventricle to the ascending
aorta. Calculation of AVA was derived from the Gorlin
equation.12,13 Transthoracic echocardiography (TEE) was
performed before TAVI, and severity of aortic and mitral valve
regurgitation was semiquantitatively graded as mild, moder-
ate, and severe according to guidelines.14
TAVI Procedure
TAVI was performed using standard techniques.12,13 Patients
underwent implantation of the self-expanding Medtronic
CoreValve (Medtronic, Minneapolis, MN) or the balloon-
expandable Edwards Sapien XT prosthesis (Edwards LifeS-
ciences, Irvine, CA), using the transfemoral, transapical, or
subclavian access route, and the self-expanding Symetis
Acurate TA prosthesis (Symetis SA, Ecublens VD, Switzerland)
using the transapical route. Selection of access route and
valve type was based on anatomical characteristics deter-
mined by contrast-enhanced computed tomography, angiog-
raphy, and TEE. Among patients with CAD, revascularization of
coronary artery segments with diameter stenosis ≥70% was
attempted by percutaneous coronary intervention (PCI) either
in a scheduled session before TAVI or at the time of TAVI
(concomitant PCI).
Measurement of Troponin
Levels of cardiac troponin T (cTnT) were determined within
12 hours post-TAVI; in case of increased levels (>19 ULN),
repetitive measurements were obtained at 24 hours and later
to assess maximal (peak) post-TAVI levels. In a subgroup of
256 patients (44.4%), levels of cTnT were available at baseline
before the procedure. cTnT measurements were performed up
to August 2010 by means of the fourth-generation Elecsys
cTnT assay and thereafter by means of the high-sensitivity
Elecsys cTnT assay (both Roche Diagnostics, Mannheim,
Germany). Based on the 99th percentile in a healthy
population and the requirement of a ≤10% coefﬁcient
variation, the upper reference limits for cTnT levels were
0.010 and 0.014 lg/L, respectively, for the 2 assays.
Clinical Follow-up
Demographic, clinical, and procedural characteristics were
systematically collected. Laboratory values during the index
hospitalization were retrieved from the central hospital
laboratory. Patients were followed throughout 2 years.
Adverse cardiac and cerebrovascular events were assessed
in-hospital, and regular follow-up was performed at 30 days,
12 months, and 2 years by means of a clinical visit or a
standardized telephone interview. All events were adjudicated
by an independent clinical event committee consisting of
invasive cardiologists and cardiac surgeons. All data were
entered into a dedicated database and held at an academic
clinical trials unit (CTU Bern, Bern University Hospital, Bern,
Switzerland) responsible for central data audits and mainte-
nance of the database.
Clinical Endpoints and Deﬁnitions
Clinical endpoints were deﬁned according to VARC-2 crite-
ria.11 Myocardial injury was deﬁned using the VARC-2 cutoff
for postprocedure cTnT (>159 ULN). The study’s primary
endpoint was all-cause mortality within 30 days. Secondary
endpoints were cardiovascular death, cerebrovascular events
(stroke, transient ischemic attack), and myocardial infarction
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(MI) at 30 days and 2 years. An exploratory analysis assessed
clinical outcomes in relation to elevated (>19 ULN) baseline,
preintervention cTnT in the subset of patients with available
measurements. Renal dysfunction was deﬁned as estimated
glomerular ﬁltration rate (GFR) <60 mL/min per 1.73 m2.
CAD was deﬁned as the presence of 1 or more lesions of the
epicardial coronary arteries with ≥50% diameter stenosis in
vessels ≥1.5 mm in diameter. For patients with CAD, the
SYNTAX score at baseline (preceding any PCI) was calculated
using the respective algorithm15 (available at: www.syntaxs-
core.com).
Statistical Analyses
Continuous variables are summarized as meanSD: categor-
ical ones, as actual numbers, and percentages. Baseline and
procedural characteristics were compared using Fisher’s tests
for binary responses, chi-square tests for more than 2
responses, and unpaired t tests for means. Median post-TAVI
troponin levels were compared using the Kruskall–Wallis test
or Mann–Whitney U test, as appropriate. Predictors of post-
TAVI cTnT levels were assessed using univariate regression
and retained in the multivariate regression if they had a
signiﬁcant effect of P<0.2. Clinical outcomes were analyzed
using Cox regression analysis (time to ﬁrst event) and
graphically presented using Kaplan–Meier curves with inci-
dence rates calculated from life tables. The independent
association between cTnT elevation and subsequent mortality
was examined using Cox proportional hazards models. Hazard
ratios (HRs) with 95% CIs, and P values were derived from the
Wald chi-square test. Adjusted HRs were calculated using
baseline variables with a uni- and/or multivariate effect
(P<0.2) on all-cause mortality at 30 days: age, renal dysfunc-
tion, and Society of Thoracic Surgeons (STS) score. Prognostic
discrimination of post-TAVI and pre-TAVI cTnT levels was
assessed by receiver operating characteristic (ROC) curves
and quantiﬁed by areas under the curve (AUCs). Findings were
considered statistically signiﬁcant at the 0.05 level. All
analyses were performed with Stata software (version 13.1;
StataCorp LP, College Station, TX).
Results
Baseline and Procedural Characteristics
Levels of cTnT were measured at 12 hours in all patients and
at 24 hours and later in 96.2% of patients. Multivariate
predictors of peak troponin levels included body weight
(P<0.001), history of MI (P=0.041), STS score (P<0.0001),
and transapical access (P<0.001; Table S1). Distribution of
post-TAVI cTnT peak levels is shown in Figure 1. VARC-2–
deﬁned myocardial injury was observed in 338 of 577
patients (58.1%). At baseline, patients with versus without
myocardial injury more frequently had renal dysfunction, CAD,
and multi vessel disease and had higher STS scores (Table 1).
Procedural characteristics of TAVI interventions are summa-
rized in Table 2. The majority of interventions (80%) were
performed by means of the femoral route; myocardial injury
occurred in 49.1% of transfemoral and 100% of transapical
interventions (P<0.001). The Metronic Corevalve was
implanted in 52%, the Edwards Sapien XT in 46%, and the
Symetis Acurate TA prosthesis in 2% of patients. The Edwards
Sapien valve was used more commonly in patients with
myocardial injury (Table 2) and was associated with higher
peak cTnT levels overall (Table 3), whereas there was no
difference in a subanalysis excluding transapical interventions
(Table 4). Concomitant PCI was performed in 16% of patients
and was not associated with frequency of myocardial injury
(P=0.91; Table 2) or with peak cTnT levels (P=0.71; Table 3).
Invasive hemodynamic measures are summarized in Table S2
and were generally not related to cTnT elevation, with the
exception of higher left ventricular ejection fraction in patients
with versus without myocardial injury (54.614.1% vs
52.115.5%; P=0.045).
Primary Endpoint: Post-TAVI Troponin in Relation
to 30-Day Mortality
Follow-up was complete by 100% at 30 days and 94.3% at
2 years. Mortality rates were 5.2% at 30 days and 24.8% at
2 years. Myocardial injury was associated with a higher risk of
all-cause death (HR, 10.33; 95% CI, 2.46–43.37; P<0.001) and
cardiovascular death at 30 days (HR, 8.50; 95% CI, 2.00–
36.07; P<0.001). Differences remained signiﬁcant after
Figure 1. Proportion of patients (n=577) across increments of
post-TAVI peak cTnT levels expressed as multiples of the upper
limit of normal (ULN). cTnT indicates cardiac troponin T; TAVI,
transcatheter aortic valve implantation.
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adjusting for independent predictors of 30-day mortality
(Table S3), which included age, renal dysfunction, and STS
score (Table 5).
Post-TAVI Troponin in Relation to 2-Year
Outcomes
VARC-2–deﬁned myocardial injury had an AUC of 0.63 (0.56–
0.67; P<0.001), sensitivity of 0.37, and speciﬁcity of 0.81 for
prediction of 2-year mortality. We did not identify a higher
cTnT cutoff with higher AUC compared with the 159 ULN
cutoff with respect to 2-year mortality. Myocardial injury was
associated with higher risk of all-cause death (HR, 2.13; 95%
CI, 1.48–3.08; P<0.001) and cardiovascular death at 2 years
(HR, 2.26; 95% CI, 1.43–3.56; P<0.001). Differences
remained signiﬁcant after multivariate adjustment (adjusted
HR, 1.98; 95% CI, 1.36–2.88; P<0.001 and adjusted HR, 2.00;
95% CI, 1.25–3.18; P=0.004, respectively; Figure 2 and
Table 5), as well as in a landmark analysis between 30 days
and 2 years (Figure 3). Myocardial injury was consistently
related to higher 2-year mortality in sensitivity analyses
including patients without renal dysfunction (n=181; 31%:
adjusted HR, 2.14; 95% CI, 1.10–4.16; P=0.026), those who
did not undergo concomitant PCI (n=486; 84%: adjusted HR,
1.84; 95% CI, 1.23–2.74; P=0.003), and those without trans
Table 1. Baseline Characteristics of the Study Population
Variable
cTnT ≤
159 ULN
n=239
cTnT >
159 ULN
n=338 P Value
Demographics
Age, y 82.45.1 82.45.8 0.99
Female sex, n (%) 135 (56) 179 (53) 0.44
Body mass index, kg/m2 26.75.2 26.04.7 0.07
Cardiac risk factors
Diabetes mellitus, n (%) 67 (28) 90 (27) 0.70
Hypercholesterolemia,
n (%)
143 (60) 225 (67) 0.11
Hypertension, n (%) 199 (83) 289 (86) 0.48
Current smoker, n (%) 17 (8) 35 (11) 0.23
Coronary artery disease, n (%) 140 (59) 227 (67) 0.036
SYNTAX score 15.511.0 17.013.2 0.28
Multivessel disease, n (%) 42 (18) 85 (25) 0.03
Previous myocardial infarction,
n (%)
34 (14) 53 (16) 0.72
Previous CABG, n (%) 20 (9) 27 (9) 1.000
Previous PCI, n (%) 56 (23) 91 (27) 0.38
Chronic obstructive pulmonary
disease, n (%)
35 (15) 64 (19) 0.18
Renal dusfunction (GFR
<60 mL/min per 1.73 m2)
145 (61) 250 (74) 0.001
Severity of aortic regurgitation,
n (%)
0.31
None/mild 215 (93) 291 (91) 0.35
Moderate/severe 16 (7) 30 (9) 0.35
Severity mitral regurgitation,
n (%)
0.75
None/mild 181 (76) 252 (75) 0.77
Moderate/severe 58 (24) 86 (25) 0.77
Left ventricular mass index,
g/m2
149.146.0 142.041.9 0.11
Atrial fibrillation, n (%) 63/204 (31) 76/268 (28) 0.61
NYHA III/IV, n (%) 181 (76) 223 (66) 0.016
CCS III/IV, n (%) 32 (13) 46 (14) 1.000
Logistic EuroScore (%) 22.114.0 23.413.6 0.25
STS score (%) 6.13.6 7.65.9 0.001
Post-TAVI CK-MB, lg/L 5.32.5 17.840.3 <0.001
CABG indicates coronary artery bypass graft; CCS, CanadianCardiovascular Society; CK-MB,
creatine phosphokinase-MB; cTnT, cardiac troponin T; GFR, glomerular ﬁltration rate; NYHA,
New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of
Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; ULN, upper limit of normal.
Table 2. Procedural Characteristics
Variable
cTnT
≤159 ULN
n=239
cTnT
>159 ULN
n=338 P Value
Access route, n (%)
Femoral 235 (98) 227 (67) <0.001
Apical 0 (0) 106 (31) <0.001
Subclavian 4 (2) 5 (1) 1.000
Valve type, n (%) <0.001
Medtronic CoreValve 151 (63) 150 (44) <0.001
Edwards Sapien valve 88 (37) 177 (52) <0.001
Symetis acurate 0 (0) 11 (3) 0.004
Concomitant PCI, n (%) 37 (15) 54 (16) 0.91
Procedural specifications, n (%)
Device success VARC-2 159 (67) 228 (67) 0.86
Procedural mortality 0 (0) 1 (0) 1.000
TAV-in-TAV deployment 1 (0) 11 (3) 0.02
Repeat unplanned
intervention within 30 days
1 (0) 3 (1) 0.65
Postimplantation mean aortic
gradient ≥20 mm Hg
5 (2) 9 (3) 0.78
Moderate/severe patient
prosthesis mismatch
58 (24) 60 (18) 0.06
Moderate/severe aortic
regurgitation
25 (10) 45 (13) 0.36
cTnT indicates cardiac troponin T; PCI, percutaneous coronary intervention; TAV:
transcatheter aortic valve; ULN, upper limit of normal; VARC, Valve Academic Research
Consortium.
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apical access (n=471; 82%: adjusted HR, 2.00; 95% CI, 1.34–
2.98; P=0.001; Tables S4 through S6; Figure S1). These
ﬁndings also held true when we excluded patients with
serious complications resulting in procedure-unrelated tro-
ponin elevation, including emergent cardiac surgery, perica-
diotomy, or ventricular rupture (n=7, all with myocardial
injury; adjusted HR, 2.01; 95% CI, 1.38–2.93; P<0.001).
Prognostic Impact of Post-TAVI Troponin in
Relation to the Presence and Complexity of CAD
CAD was present in 367 patients (64%). Myocardial injury was
more frequent in patients with versus without CAD (61.8% vs
52.8%; P=0.036). Event rates were lowest in patients without
CAD and no myocardial injury and highest in those with CAD
and myocardial injury (2-year mortality 11.6% vs 33.1%,
respectively; Figure 4 and Table 6). The association of
myocardial injury with 2-year mortality was consistent in
patients without CAD (adjusted HR, 2.59; 95% CI, 1.27–5.26;
P=0.009) and those with CAD (adjusted HR, 1.71; 95% CI,
1.10–2.65; P=0.018: P for interaction=0.24; Figure 4). When
patients with CAD were further stratiﬁed according to CAD
complexity, highest event rates were observed in patients
with SYNTAX scores >22 and myocardial injury (n=64; 2-year
mortality, 41.1%).
Exploratory Analysis: Pre-TAVI Troponin in
Relation to Outcomes
Among patients with pre-TAVI cTnT measurement, 192 (75%)
had preprocedure cTnT levels >19 ULN. Patients with versus
without pre-TAVI cTnT elevation had a higher risk of death at
30 days (HR, 9.05; 95% CI, 0.55–150.10; P=0.043) and at
2 years (HR, 2.86; 95% CI, 1.30–6.31; P=0.009; Table S7).
Pre-TAVI cTnT elevation (>19 ULN) compared with post-TAVI
myocardial injury (cTnT>159 ULN) showed inferior prognostic
discrimination for 30-day mortality (AUC, 0.71 [0.59–0.83] vs
0.79 [0.71–0.87], respectively; P=0.09 between curves), but
similar performance for 2-year mortality (AUC, 0.66 [0.58–
0.74] vs 0.63 [0.56–0.67]; P=0.67 between curves).
Discussion
The main ﬁndings of the present analysis, the largest study to
date assessing the prognostic implications of cTnT elevation
post-TAVI and the ﬁrst to examine the impact of VARC-2–
deﬁned myocardial injury on long-term clinical outcomes, can
be summarized as follows: (1) Postprocedural cTnT elevation
above the VARC-2 cutoff (>159 ULN) was observed in more
than half of patients undergoing TAVI, it was a strong,
independent predictor of 30-day mortality, and remained a
modest, but signiﬁcant, predictor of mortality within 2 years
after the intervention; (2) whereas myocardial injury was more
common in patients with CAD, its predictive impact was
consistent in patients with and without CAD; (3) occurrence of
myocardial injury as well as presence and complexity of
underlying CAD had a synergistic effect on prognosis, with 4-
fold higher 2-year mortality risk in patients with SYNTAX
scores >22 and post-TAVI myocardial injury compared to
those without CAD and no myocardial injury; and (4)
preintervention cTnT levels above the ULN did not confer
superior prognostic value compared with VARC-2–deﬁned
postprocedure myocardial injury. Together, these ﬁndings
advance previous conﬂicting evidence—derived from smaller
studies with shorter follow-up durations and heterogeneous
cTn cutoffs—regarding the clinical signiﬁcance of myocardial
injury in patients undergoing TAVI.
Table 3. Post-TAVI Troponin T Levels in Relation to Access
Route, Valve Type, and Concomitant PCI
N Median 9ULN (IQR) P Value
Overall 577 17.7 (10.1–32.5)
Procedural access <0.001*
Femoral 462 14.8 (9.3–24.3)
Transapical 106 43.7 (29.8–63.3)
Subclavian 9 20.2 (7.3–61.4)
Device <0.001*
Medtronic CoreValve 301 15.0 (9.3–25.4)
Edwards Sapien XT 265 21.3 (12.0–38.8)
Symetis Acurate 11 49.1 (39.1–86.6)
Concomitant PCI 0.71†
Yes 91 17.5 (9.8–36.2)
No 486 17.9 (10.1–31.7)
IQR indicates interquartile range; PCI, percutaneous coronary intervention; TAVI;
transcatheter aortic valve implantation; ULN, upper limit of normal.
*Kruskall–Wallis tests.
†Mann–Whitney U test.
Table 4. Frequency of Myocardial Injury in Relation to Valve
Type in the Subgroup of Patients Who Underwent
Transfemoral or Subclavian TAVI (n=471)
Valve Type
cTnT ≤159 ULN
(No Myocardial
Injury)
cTnT >159 ULN
(Myocardial
Injury) P Value
Medtronic CoreValve,
n (%)
150 (49.8) 151 (50.2) 0.74
Edwards Sapien XT,
n (%)
82 (48.2) 88 (51.8)
cTnT indicates cardiac troponin T; ULN, upper limit of normal.
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Myocardial biomarkers increase commonly post-TAVI.5–8
Whereas procedure-related cTn elevation predicts adverse
events after coronary revascularization4,16 as well as surgical
aortic valve replacement,17 the clinical signiﬁcance of
increased cTn post-TAVI has been a matter of debate.
Rodes-Cabau et al. showed that the magnitude of cTnT
elevation was related to cardiac, but not all-cause, mortality in
101 patients followed for 910 months (with 46 of those
patients having ≥6-month follow-up).5 Similarly, Yong et al.
found that myocardial injury, deﬁned as increase of creatine
phosphokinase-MB (CK-MB) and/or cTnT >59 ULN, indepen-
dently predicted 30-day mortality.6 In sharp contrast, other
studies did not conﬁrm the predictive utility of any cTn
elevation9 or of cTn increase >159 ULN.8 These conﬂicting
outcomes may be related to small sample sizes, low numbers
of events, use of different cTn isoforms, T5,6 or I,8 which have
shown dissimilar prognostic performance in different clinical
settings,18 or heterogeneity of cTn cutoffs to deﬁne myocar-
dial injury—although ﬁndings were discordant even between
the 2 studies that applied the same VARC-2–deﬁned thresh-
old.5,8
Against this background, the present study of 577
consecutive patients demonstrates a signiﬁcant association
between VARC-2–deﬁned cTnT elevation and clinical out-
comes. The mortality risk was particularly pronounced within
the early postprocedural period, but persisted over time and
remained signiﬁcant over 2 years, including a landmark
analysis between 30 days and 2 years. Importantly, these
results held true in sensitivity analyses excluding potential
confounders of cTnT elevation (ie, renal dysfunction), con-
comitant PCI, and transapical intervention. It is important to
note that the predictive merit was only modest for 2-year
outcomes; hence, it needs to be viewed in conjunction with
established, stronger risk predictors. The AUC for 2-year
mortality in this study is similar to that reported previously
with regard to 9-month survival.5 The reasonably high
speciﬁcity, but low sensitivity, further indicate that the
presence, but not the absence, of myocardial injury may be
Table 5. Clinical Outcomes at 30 Days and 2 Years in Relation to Post-TAVI Troponin T >159 ULN Versus ≤159 UNL
Outcome
cTnT ≤159 ULN
n=239
cTnT >159 ULN
n=338 Hazard Ratio (95% CI) P Value
Adjusted Hazard
Ratio (95% CI)
Adjusted
P Value
30 days
Death, n (%) 2 (0.8) 28 (8.3) 10.33 (2.46–43.37) 0.001 8.77 (2.07–37.12) 0.003
Cardiovascular death, n (%) 2 (0.8) 23 (6.9) 8.50 (2.00–36.07) 0.004 6.95 (1.62–29.84) 0.009
Cerebrovascular events, n (%) 6 (2.5) 15 (4.5) 1.79 (0.70–4.63) 0.23 1.44 (0.55–3.77) 0.45
Major stroke, n (%) 3 (1.3) 15 (4.5) 3.61 (1.05–12.47) 0.04 2.99 (0.86–10.44) 0.09
Minor stroke, n (%) 1 (0.4) 0 (0.0) 0.24 (0.01–5.87) 0.41
Transient ischemic attack, n (%) 2 (0.8) 0 (0.0) 0.14 (0.01–2.90) 0.17
Myocardial infarction, n (%) 0 (0.0) 3 (0.9) 4.95 (0.26–95.39) 0.27
Death or major stroke, n (%) 4 (1.7) 35 (10.4) 6.42 (2.28–18.06) <0.001 5.32 (1.87–15.11) 0.002
Death, major stroke, or MI, n (%) 3 (1.3) 37 (11.0) 9.11 (2.81–29.53) <0.001 7.56 (2.31–24.74) 0.001
Major or life-threatening bleeding, n (%) 55 (23.0) 135 (40.0) 1.85 (1.35–2.53) <0.001 1.81 (1.31–2.48) <0.001
Major vascular complications, n (%) 21 (8.8) 32 (9.5) 1.08 (0.62–1.87) 0.781 1.00 (0.57–1.76) 0.989
2 years
Death, n (%) 39 (17.0) 104 (31.9) 2.13 (1.48–3.08) <0.001 1.98 (1.36–2.88) <0.001
Cardiovascular death, n (%) 25 (11.1) 71 (22.6) 2.26 (1.43–3.56) <0.001 2.00 (1.25–3.18) 0.004
Cerebrovascular events, n (%) 14 (6.3) 24 (8.1) 1.31 (0.68–2.54) 0.42 1.21 (0.62–2.37) 0.58
Major stroke, n (%) 8 (3.6) 19 (6.0) 1.80 (0.79–4.11) 0.16 1.69 (0.73–3.90) 0.22
Minor stroke, n (%) 2 (0.9) 1 (0.4) 0.39 (0.04–4.30) 0.44 0.40 (0.04–4.50) 0.46
Transient ischemic attack, n (%) 4 (1.8) 3 (1.3) 0.59 (0.13–2.65) 0.49 0.51 (0.11–2.32) 0.38
Myocardial infarction, n (%) 2 (0.9) 10 (3.5) 3.96 (0.87–18.06) 0.08 3.62 (0.78–16.93) 0.10
Death or major stroke, n (%) 44 (19.1) 112 (34.2) 2.04 (1.44–2.89) <0.001 1.91 (1.34–2.72) <0.001
Death, major stroke, or MI, n (%) 44 (19.1) 117 (35.7) 2.17 (1.53–3.07) <0.001 2.04 (1.43–2.90) <0.001
Depicted are number of ﬁrst events (% cumulative incidence), hazard ratios (HRs) with respective 95% CI from Cox’s regressions. Adjusted HRs were obtained after adjusting for age, renal
dysfunction, and STS score. Age, renal dysfunction, and STS score had a P<0.2 univariate effect on the primary outcome all-cause death at 30 days. Missing data were singly imputed (n=1
for renal dysfunction and n=1 for STS score). cTnT indicates cardiac troponin T; MI, myocardial infarction; STS, Society of Thoracic Surgeons; ULN, upper limit of normal.
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prognostically meaningful. Patients with evidence of peripro-
cedural myocardial injury have considerable likelihood to
experience adverse outcomes; in contrast, absence of
myocardial injury does not preclude an unfavorable subse-
quent prognosis in a substantial proportion of such patients.
The cutoff to deﬁne procedural myocardial injury post-TAVI
increased form 109 ULN in the VARC consensus document19
to 159 ULN in the VARC-2 deﬁnition,11 largely based on the
study by Rodes-Cabau et al., who found that this higher cutoff
better predicted adverse outcomes.5 By associating cTnT
elevation >159 ULN with 10-fold higher mortality at 30 days
and 2-fold increased mortality at 2 years, the present study
supports the current VARC-2 deﬁnition as a clinically mean-
ingful, prognostically relevant cutoff of post-TAVI cTn
increase. Unlike elective PCI procedures, where cTn cutoffs
higher than the respective diagnostic thresholds for peripro-
cedural MI enhance prognostication,20 in this cohort of TAVI
patients, greater magnitudes of cTnT elevation did not provide
incremental prognostic information compared with the VARC-
2–deﬁned cutoff.
Coronary atherosclerosis frequently coexists in patients
with AS and adversely affects TAVI outcomes.10,21 This study
is the ﬁrst to assess the interrelated impact of myocardial
injury and underlying CAD on patient prognosis. We found
Figure 2. Cumulative event curves for all-cause mortality (A) and cardiovascular death
within 2-year follow-up (B) in patients with or without post-TAVI cTnT elevation >159 ULN.
cTnT indicates cardiac troponin T; HR, hazard ratio; TAVI, transcatheter aortic valve
implantation; Trop, troponin; ULN, upper limit of normal.
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that the association of VARC-2 myocardial injury with 2-year
outcomes was consistent, irrespective of coronary status.
Moreover, by quantifying the complexity of CAD by means of
the SYNTAX score—an established angiographic tool for this
purpose—we were able to identify patients with lowest
mortality post-TAVI (ie, patients without CAD and no myocar-
dial injury) versus 4-fold higher risk (those with SYNTAX score
>22 and myocardial injury). Previous analyses focusing solely
on CAD complexity reported 1.6-fold higher death and 2.4-
fold higher cardiac death rates post-TAVI in patients with
SYNTAX score >22 versus patients without CAD.10 Thereby,
our ﬁndings advance previous evidence of an escalating risk
of adverse TAVI outcomes across increasingly complex
CAD10,22 by indicating that detection of procedure-related
Figure 3. Landmark analysis of the cumulative incidence of all-cause mortality between
30 days and 2 years in patients with or without post-TAVI cTnT elevation >159 ULN. Adj.
HR indicates adjusted hazard ratio; cTnT, cardiac troponin T; HR, hazard ratio; TAVI,
transcatheter aortic valve implantation; Trop, troponin; ULN, upper limit of normal.
Figure 4. Kaplan–Meier graphs of the cumulative incidence of all-cause mortality at
2 years in patients stratiﬁed according to presence of coronary artery disease (CAD) and
according to post-TAVI cTnT elevation >159 ULN. Adj. HR indicates adjusted hazard ratio;
cTnT, cardiac troponin T; HR, hazard ratio; TAVI, transcatheter aortic valve implantation;
Trop, troponin; ULN, upper limit of normal.
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cTnT elevation substantially reﬁnes risk stratiﬁcation in this
setting.
The mechanisms of troponin release during TAVI are likely
multifactorial. First, direct myocardial damage is induced by
mechanical compression of the left ventricular outﬂow tract
during balloon dilatation and valve implantation and—to a
greater extent—by myocardial puncture during transapical
interventions. Second, some,23 but not all, mechanistic
studies employing magnetic resonance imaging24 pointed to
the primary role of distal embolization of calcium micropar-
ticles into the coronaries during valvuloplasty and prosthesis
implantation—a mechanism that is consistent with preclinical
evidence25 as well as evidence of cerebrovascular microem-
boli post-TAVI.26 Third, temporary hypotension during rapid
pacing or balloon predilatation, excessive bradycardia
because of conduction abnormalities, or, conversely, tachy-
cardia in the setting of inotropic hemodynamic support can
result in myocardial ischemia attributed to hypoperfusion of
the typically hypertrophic myocardium. Along these lines, it is
reasonable to assume that myocardial supply-demand mis-
match during the intervention is exacerbated, and thus cTn
release is augmented in the presence of obstructive coronary
lesions; this is supported by our ﬁndings of more-frequent
myocardial injury in patients with CAD, particularly multives-
sel disease. Previous studies have been discordant by
showing no difference of CAD status5,6 or higher prevalence
of CAD in patients with TAVI-related myocardial injury.8
Relevant to the aforementioned mechanisms, measures
that could theoretically attenuate myocardial injury during
TAVI include optimization of hemodynamic support to avoid
prolonged episodes of hypotension, shortening of rapid
pacing, cautious use of balloon dilatation (clearly to the
extent that is anatomically and clinically feasible), appropriate
balloon and device sizing to minimize direct myocardial injury,
possibly revascularization before TAVI procedures, and ensur-
ing that transapical interventions are reserved only for
patients who absolutely cannot undergo transarterial TAVI.
Dedicated studies would be required to assess the impact of
beta-blockers or medications with anti-ischemic properties on
the ensuing myocardial injury and to determine possible
clinical beneﬁts.
One can speculate on the mechanistic relationship
between myocardial injury and adverse prognosis. The fact
that CAD was more common in patients with versus without
myocardial injury may, in part, be a link between more-
extensive troponin release in the acute phase and impaired
survival in the long term. Moreover, microvascular dysfunction
—which is common in the presence of long-standing AS,27 is
related to ischemia-induced arrhythmias and ominous prog-
nosis irrespective of epicardial CAD28 and is only in part
Table 6. Clinical Outcomes at 30 Days and 2 Years in Relation to Presence of CAD and Post-TAVI Troponin >159 ULN vs ≤159
ULN
No CAD
Adjusted HR
(95% CI)
Adjusted
P Value
CAD
Adjusted HR
(95% CI)
Adjusted
P Value
cTnT
≤159 ULN
n=99
cTnT
>159 ULN
n=111
cTnT
≤159 ULN
n=140
cTnT
>159 ULN
n=227
30 days
Death, n (%) 2 (2.0) 8 (7.2) 2.42 (0.50–11.59) 0.270 0 (0.0) 20 (8.8)
Cardiovascular death, n (%) 2 (2.0) 6 (5.5) 1.72 (0.34–8.76) 0.512 0 (0.0) 17 (7.5)
Cerebrovascular events 3 (3.0) 9 (8.1) 2.41 (0.64–9.10) 0.196 3 (2.1) 6 (2.7) 0.88 (0.21–3.70) 0.857
Death or major stroke, n (%) 3 (3.0) 12 (10.8) 2.79 (0.77–10.09) 0.118 1 (0.7) 23 (10.1) 12.70 (1.70–94.77) 0.013
Death, major stroke,
or MI, n (%)
2 (2.0) 13 (11.7) 4.59 (1.01–20.73) 0.048 1 (0.7) 24 (10.6) 13.28 (1.78–98.87) 0.012
2 years
Death, n (%) 11 (11.6) 30 (29.5) 2.59 (1.27–5.26) 0.009 28 (20.8) 74 (33.1) 1.71 (1.10–2.65) 0.018
Cardiovascular death, n (%) 6 (6.4) 17 (17.5) 2.39 (0.91–6.26) 0.076 19 (14.4) 54 (25.0) 1.77 (1.04–3.01) 0.035
Cerebrovascular events 5 (5.3) 11 (10.8) 1.89 (0.64–5.57) 0.248 9 (7.0) 13 (6.8) 0.90 (0.38–2.14) 0.818
Death or major stroke, n (%) 14 (14.8) 35 (34.0) 2.38 (1.26–4.50) 0.008 30 (22.2) 77 (34.4) 1.67 (1.09–2.56) 0.019
Death, major stroke,
or MI, n (%)
12 (12.7) 35 (33.9) 2.81 (1.44–5.51) 0.003 32 (23.7) 82 (36.6) 1.71 (1.13–2.58) 0.011
Depicted are number of ﬁrst events (% cumulative incidence), hazard ratios (HRs) with respective 95% CIs from Cox’s regressions. Adjusted HRs were obtained after adjusting for age, renal
dysfunctions and STS score. Age, renal dysfunctions and STS score had a P<0.2 univariable effect on the primary outcome all-cause death at 30 days. Missing data were singly imputed
(n=1 for renal dysfunction and n=1 for STS score). CAD indicates coronary artery disease; cTnT, cardiac troponin T; MI, myocardial infarction; STS, Society of Thoracic Surgeons; TAVI;
transcatheter aortic valve implantation; ULN, upper limit of normal.
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reversible after replacement of the stenotic valve29—may
have been more pronounced in patients (with or without CAD)
with myocardial injury, but this remains purely speculative.
Although this observational study cannot elucidate mecha-
nisms responsible for unfavorable outcomes in patients with
profound cTn elevation, our ﬁndings are consistent with
previous investigations with short- and mid-term follow-up5–7
and are corroborated further by the large, consecutive sample
size.
In the setting of PCI, preintervention cTn levels better
predict outcomes compared with post-PCI cTn rise.30 While
minor cTn elevation provides prognostic information in
patients with severe AS treated medically or with surgical
valve replacement,31 the relative value of pre-TAVI cTn
elevation versus post-TAVI myocardial injury is unknown. In
this study, minor pre-TAVI cTnT elevation above the ULN was
observed in three quarters of patients and did not outperform
the predictive merit of post-TAVI increase >159 ULN.
Although this exploratory analysis is limited by the availability
of pre-TAVI cTnT measurements in only half of all patients, it
represents the largest cohort to date assessing the impact of
baseline cTn levels on subsequent TAVI outcomes.
This study advances current evidence of the clinical
signiﬁcance of myocardial injury in TAVI in several ways.
First, given the conﬂicting results of previous smaller studies
regarding the presence5,6 of absence8,9 of a prognostic value
of myocardial injury, this study—with a population larger than
the sum of all previous reports—indicates that troponin
elevation is a strong predictor of 30-day mortality and remains
a signiﬁcant, albeit modest, predictor at 2 years. Second,
against a background of discordant ﬁndings regarding the
current VARC-2 deﬁnition of myocardial injury,5,8 this analysis
provides validation of the VARC-2 cutoff over other possible
values as a meaningful threshold for patient prognostication.
Third, given the established adverse impact of concomitant
CAD on TAVI outcomes,10,21 we demonstrate that risk
stratiﬁcation can be enhanced substantially by means of
combined assessment of CAD complexity and periprocedural
troponin elevation. Fourth, the observation that—unlike
PCI30—preintervention troponin does not outperform the
prognostic value of post-TAVI troponin elevation is a novel
ﬁnding that merits further investigation.
Study Limitations
This study has several limitations owing to its observational
nature. First, although all data were prospectively collected,
this is a retrospective, single-center analysis and is subject to
the limitations common to such analyses. Second, cTnT was
not measured at prespeciﬁed time points postintervention;
however, cTnT was measured in all patients at 12 hours and
again at 24 hours and later in case of increased 12-hour
values (ie, in 96.2% of patients); hence, it is unlikely that peak
cTnT values were not recorded in this population. Third, the
mechanisms responsible for the association of cTnT elevation
with subsequent outcomes cannot be fully elucidated in this
clinical observational study; dedicated mechanistic studies
are more suited to address this issue.23,24,32
Conclusions
VARC-2–deﬁned cTnT elevation emerged as an independent
predictor of 30-day mortality and remained a modest, but
signiﬁcant, predictor of 2-year mortality post-TAVI. Presence
of troponin elevation appears to be prognostically relevant,
whereas absence of myocardial injury does not preclude an
adverse prognosis, as reﬂected by a reasonably high speci-
ﬁcity but low sensitivity. Complexity of underlying CAD
modiﬁed the prognostic value of myocardial injury, with
highest mortality risk in patients combining SYNTAX score
>22 and troponin elevation. These ﬁndings may have
implications for reﬁning risk stratiﬁcation in patients treated
with TAVI and for employing preventive measures to reduce
procedural myocardial injury during TAVI interventions.
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